Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lebowitz

Showing results (1051-1060 of 1,066) with videos related to

Pageof 107
Sort By:
Scientific Reports|November 20, 2024
The association between salivary oxytocin, age, and puberty in children with and without OCDAnna-Rosa Cecilie Mora-Jensen, Line Katrine Harder Clemmensen, Manja Gersholm Grønberg, et al.
The Journal of Biological Chemistry|September 5, 2019
Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in miceJoseph C Chen, Amanda R Luu, Nathan Wise, et al.
Expert Review of Neurotherapeutics|October 9, 2009
Provisional diagnostic criteria for depression of Alzheimer's disease: description and reviewJason T Olin, Lon S Schneider, Ira R Katz, et al.
Eclinicalmedicine|November 15, 2021
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialNiklaus D Labhardt, Mikaela Smit, Ianis Petignat, et al.
The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Molecular Therapy. Methods & Clinical Development|July 1, 2017
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B MiceMika Aoyagi-Scharber, Danielle Crippen-Harmon, Roger Lawrence, et al.
Drug Delivery and Translational Research|January 17, 2020
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type BAnita Grover, Danielle Crippen-Harmon, Lacey Nave, et al.
Human Mutation|July 26, 2019
Assessment of predicted enzymatic activity of α-N-acetylglucosaminidase variants of unknown significance for CAGI 2016Wyatt T Clark, Laura Kasak, Constantina Bakolitsa, et al.
The Journal of Biological Chemistry|October 28, 2022
Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunctionJenna Magat, Samantha Jones, Brian Baridon, et al.
Pageof 107

Showing results (1051-1060 of 1,066) with videos related to

Sort By:
Pageof 107
Scientific Reports|November 20, 2024
The association between salivary oxytocin, age, and puberty in children with and without OCDAnna-Rosa Cecilie Mora-Jensen, Line Katrine Harder Clemmensen, Manja Gersholm Grønberg, et al.
The Journal of Biological Chemistry|September 5, 2019
Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in miceJoseph C Chen, Amanda R Luu, Nathan Wise, et al.
Expert Review of Neurotherapeutics|October 9, 2009
Provisional diagnostic criteria for depression of Alzheimer's disease: description and reviewJason T Olin, Lon S Schneider, Ira R Katz, et al.
Eclinicalmedicine|November 15, 2021
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialNiklaus D Labhardt, Mikaela Smit, Ianis Petignat, et al.
The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Molecular Therapy. Methods & Clinical Development|July 1, 2017
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B MiceMika Aoyagi-Scharber, Danielle Crippen-Harmon, Roger Lawrence, et al.
Drug Delivery and Translational Research|January 17, 2020
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type BAnita Grover, Danielle Crippen-Harmon, Lacey Nave, et al.
Human Mutation|July 26, 2019
Assessment of predicted enzymatic activity of α-N-acetylglucosaminidase variants of unknown significance for CAGI 2016Wyatt T Clark, Laura Kasak, Constantina Bakolitsa, et al.
The Journal of Biological Chemistry|October 28, 2022
Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunctionJenna Magat, Samantha Jones, Brian Baridon, et al.
Pageof 107